Financial Comparison
AbbVie Inc. vs Johnson & Johnson
Click a ticker to view the full analysis.
In short
Johnson & Johnson is the more profitable of the two, keeping 28.5% of revenue as net profit against 6.9% for AbbVie Inc. AbbVie Inc. trades at the higher trailing P/E (77.0× vs 29.7× for Johnson & Johnson), so investors pay more for each dollar of its earnings. Fisclear flags 1 medium- or high-severity risk for AbbVie Inc. and 1 for Johnson & Johnson.
Based on filings for periods ending 30 Jun 2026 (ABBV) and 28 Jun 2026 (JNJ) · Updated
FisclearScore Comparison
FisclearScore is a quantitative model. ABBV shown solid · JNJ shown dashed. Not financial advice.
| Metric | ABBV | JNJ |
|---|---|---|
| Price | $272.42 | $256.48 |
| Market Cap | $481.4B | $618.1B |
| P/E (TTM) | 77.0x | 29.7x |
| P/B | — | 7.3x |
| Beta | 0.23 | 0.21 |
| Div Yield | 2.46% | 2.03% |
| Revenue (TTM) | $61.2B | $94.2B |
| Net Income | $4.2B | $26.8B |
| Gross Margin | — | 67.9% |
| Risk Flags | 2 flags | 1 flag |
Related comparisons
Data sourced from SEC EDGAR, Yahoo Finance, and official exchange filings. For informational purposes only. Not financial advice.